@grandslam.. Yeah, all that stuff, and a bunch of other stuff, has been in their various filings since the IPO announcement. They're just copying and pasting it. I guess the bright side is they're not hiding anything nowadays, relative to core issues and financials. The story is there for all to see.
In the end, they will either get the funding needed for the clinical trials or they won't. They bet the farm on going legitimate with domestic approvals, so these clinical trials are the ballgame now. But the IPO is probably a hard sell with control of the company in the hands of so few people. Fortunately, Zamora isn't one of them anymore (I suspect that was a sticking point early on, necessitating his recent ejection from leadership). But I'd bet it's still a problem.
One of the spreadsheet models I played with when I started looking at IPO possibilities back in the fall was the possibility of key stakeholders being required to sell into the IPO, to reduce their control going forward. I have no idea if that kind of thing is done, but it would solve a number of problems. Unfortunately, they are not saying anything about the IPO publicly (I assume they can't even if they wanted to). It's going on 5 months, and their burn rate is higher than it used to be. Something has to give soon, or they're going to run out of money. And it's hard to believe they would be that staggeringly near-sighted, after decades of promising research.
